[{"indications": "Indications\u00a0major depression", "name": "REBOXETINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.3 Antidepressant drugs", "4.3.4 Other antidepressant drugs"], "cautions": "Cautions\u00a0history of cardiovascular disease and epilepsy; bipolar disorder; urinary retention; prostatic\r\nhypertrophy; susceptibility to angle-closure\r\nglaucoma; avoid abrupt withdrawal; interactions: Appendix 1 (reboxetine)", "side-effects": "Side-effects\u00a0nausea, dry mouth, constipation, anorexia; tachycardia,\r\npalpitation, vasodilation, postural hypotension; headache, insomnia,\r\ndizziness; chills; impotence; urinary retention; impaired visual accommodation;\r\nsweating; lowering of plasma-potassium concentration on prolonged\r\nadministration in the elderly; very rarely angle-closure\r\nglaucoma; also reported vomiting, hypertension, paraesthesia,\r\nagitation, anxiety, irritability, hallucinations, aggression, Raynaud\u2019s\r\nsyndrome, hyponatraemia, testicular pain, cold extremities,\r\nand rash; suicidal behaviour (see Suicidal Behaviour and Antidepressant\r\nTherapy)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/60899.htm", "doses": ["4\u00a0mg twice daily increased if necessary after 3\u20134 weeks\r\nto 10\u00a0mg daily in divided doses, max. 12\u00a0mg daily; child under 18 years and elderly not recommended"], "pregnancy": "Pregnancy\u00a0use only if potential benefit outweighs risk\u2014limited\r\ninformation available"}]